Activity

VIEW RECORDING - 18 mins (No highlights) Introductions and context @ 0:00 The meeting began with introductions, as some participants had not met before. Raleigh, Kevin, and Nicole from UTAK Laboratories provided background on their roles and tenure at the company. The group then discussed the purpose of the meeting - to address a cost increase for defibrinated plasma. Cost increase for defibrinated plasma @ 3:04 Raleigh acknowledged that UTAK had not properly communicated the upcoming cost increase for defibrinated plasma. He explained that UTAK has been trying to suppress the cost increase as much as possible, but the rising costs from supplier banks and blood banks, especially since COVID, have made it unsustainable. Raleigh offered to provide the deepest discount available to Somagen. Navigating customer contracts @ 4:02 Sylvain and Harpinder from Somagen discussed their customer contracts for the defibrinated plasma product. Many are up for renewal in the next month or so, which provides an opportunity to renegotiate pricing. However, Sylvain noted that Somagen's government and healthcare customers have strict policies around price increases, making it challenging to pass along the full cost increase. Potential product discontinuation @ 7:00 Kevin from UTAK mentioned that they have considered discontinuing the defibrinated plasma product entirely, as the demand has been very low until recently. However, he expressed a willingness to work with Somagen to honor their existing customer contracts through the end of November, before implementing the new pricing. Improving transparency and planning @ 13:00 Sylvain requested more visibility into UTAK's future pricing plans, ideally by the end of Q3 or early Q4, to help Somagen plan ahead with their customers. Raleigh and Kevin agreed to work on providing that information, acknowledging the importance of transparency and advance planning to support the partnership.